Brief Report: Proposed clinical trial guidelines based on clinicopathological heterogeneity of metastatic pulmonary large cell neuroendocrine carcinoma (LCNEC) - PubMed
5 hours ago
- #LCNEC
- #Clinical Trials
- #Heterogeneity
- Proposed clinical trial guidelines for metastatic pulmonary large cell neuroendocrine carcinoma (LCNEC) based on its clinicopathological heterogeneity.
- Retrospective analysis of 137 patients with metastatic LCNEC, including 100 pure and 37 mixed histologies, and 15 with transformed LCNEC (tLCNEC).
- Genomic data from 115 cases classified 55% as NSCLC-like and 37% as SCLC-like, but overall survival (median 10.0 months for primary LCNEC) showed no statistical difference between NSCLC or SCLC treatment regimens.
- No significant benefit observed from adding immunotherapy to chemotherapy; tLCNEC patients had longer median OS (16.3 months) and some achieved long-term disease control with local therapies for oligometastatic disease.
- Guidelines proposed for prospective trials of novel therapeutics due to poor outcomes and unmet needs, emphasizing the heterogeneity of LCNEC.